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View OnlineDevelopment of a fluorescent method for detecting the onset of coagulation in
human plasma on microstructured lateral flow platforms†
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DOI: 10.1039/c0an00907eMicrofluidic devices and microsystems have been used to develop blood coagulation monitoring
devices for point of care diagnostic use. However, many of them suffer from inherent variability and
imprecision, partly due to the fact that they only detect changes in bulk clotting properties and do not
reflect the microscopic nature of blood coagulation. This work demonstrates microstructured lateral
flow platforms used in combination with fluorescently labelled fibrinogen to detect microscopic clot
formation. Plasma samples applied to platforms modified with coagulation activation reagents and
fluorescent fibrinogen produced changes in fluorescence intensity due to incorporation of the
fluorophore into the forming microclots. It was found that the change in the distribution of the
fluorescence within the sample over time was an excellent predictor of the onset of coagulation, which
could be used to determine the clotting time. The impact of various assay parameters was optimised and
the assay was shown to be capable of measuring the effect of heparin concentration on blood clotting
time from 0 to 1.5 U mL1.Introduction
The monitoring of a person’s blood clotting status is critical in
identifying coagulation disorders and monitoring the effect of
anticoagulant or procoagulant drug therapies for a wide variety
of conditions and associated medical procedures. For these
reasons, tests for measuring blood coagulation are some of the
most widely used in the clinical environment. They typically
measure how long it takes for an individual’s blood to clot when
clotting is activated in a controlled and reproducible manner.
Several distinct tests are available which activate coagulation via
particular pathways and they give different information on the
individual’s clotting status.1 However, in general, all these tests
measure the same parameter which is the conversion of the liquid
blood to a gel-like solid. This is the end-point of coagulation and
is due to the conversion of soluble fibrinogen into an insoluble
fibrin network. Thus, most tests detect this change in bulk
viscosity which accompanies this process and the time it takes to
occur.2 However, the available techniques for monitoring this
change in bulk viscosity are inherently imprecise. This is due, inaBiomedical Diagnostics Institute, National Centre for Sensor Research,
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bThe Biomedical Devices and Assistive Technology Research Group,
College of Engineering and Built Environment, Dublin Institute of
Technology, Bolton St, Dublin, 1, Ireland
cDepartments of Mechanical & Aerospace Engineering and Biomedical
Engineering, University of Florida, Gainesville, Florida, 32611-6250, USA
dDepartment of Applied Sciences, University of the West of England,
Coldharbour Lane, Bristol, BS16 1QY, UK
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This journal is ª The Royal Society of Chemistry 2011part, to the inherent variability in the constitution of any given
blood sample and to the very nature of the clotting process.3–8
The kinetics of coagulation have been studied and have been
defined as a stochastic process with significant inherent
randomness.9 Coagulation is a cascade with multiple steps with
associated positive feedback loops. The process requires an
initiation step which triggers this sequence of events. When
performed in vitro, the precise time and location of this event is
difficult to ascertain. Indeed, triggering of coagulation may take
place in multiple locations at slightly different times. Thus, the
bulk change in viscosity reflects the macroscopic outcome of this
unpredictable process and results in significant variability10
typically in excess of 10% RSD. The development of techniques
that take into account the spatial and temporal changes in
viscosity could significantly enhance the quality and utility of this
measurement process.
Point of care assay devices and diagnostics are being revolu-
tionised by emerging materials and technologies such as micro-
systems and microfluidics. The ability to control the interaction
of biological samples with assay reagents in a controlled and
reproducible manner in a miniaturised format allows for low
volume, rapid testing with minimal intervention of a user.11 The
use of processing techniques which create devices with excellent
reproducibility and defined surface chemistry properties has been
essential for such devices. These properties define how the sample
interacts with the device platform and allows precise control of
fluid movement. Capillary force has been used extensively in lab-
on-a-chip systems to induce such movement and has typically
been driven by interfacial forces at a fluid/capillary boundary.12,13
However, such configurations can have disadvantages such asAnalyst
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View Onlinethe low surface area-to-volume ratio which reduces the efficiency
of interaction between immobilised reagents and the sample
under laminar flow conditions.14 This also affects the efficiency of
the capillary pulling force. Other techniques for inducing capil-
lary flow on such platforms include using arrays of micropro-
jections which individually induce a capillary force, and in
concert create a uniform and reproducible capillary force along
a lateral flow pathway. Several efforts using this technique have
been reported.14–18 Many such systems are replacing less reliable
materials such as nitrocellulose in lateral flow bioassays. Addi-
tional material properties such as optical transparency and low
fluorescence make them suitable in combination with optical and
fluorescence transduction. Materials such as glass are excellent
for prototyping purposes and other emerging materials such as
the cyclic polyolefins have excellent processability and optical
characteristics for device mass production.19–21
In this work, a technique was developed to identify the onset of
coagulation at the microscopic level, taking into account both
the spatial and temporal changes involved. This was achieved by
the incorporation of a fluorescent marker within the nascent clot
and monitoring its distribution over time. It was found that the
change in this distribution was closely correlative with the onset
of clotting as evidenced by the formation of fibrin fibres when
performed on microstructured surfaces made from either plastics
or glass. The change in distribution of the label could be
enhanced and optimised with deposition of coagulation reagents
and the location for monitoring fluorescence. The assay and
platform were shown to be capable of measuring the effect of an
anti-coagulant drug on sample clotting time.Experimental
Development of a fluorescent assay for the detection of clot
formation was investigated on two microstructured substrates;
one polymer and one glass. The polymeric platform (Fig. 1a) was
composed of cyclic polyolefin (Zeonor) and was fabricated via
injection molding (4Castchip model B2.2, A˚mic BV, Uppsala,
Sweden) forming micropillar projections of 65–70 mm in height,
top diameter ca. 50 mm, base diameter ca. 70 mm, distance
between the centres of the pillars in a row of 85 mm, and distance
between the centres of the pillars in a column of 185 mm. The
second platform was made from glass and was fabricated using
conventional photolithography and chemical etching (Fig. 1b).
The device consisted of 2 mm wide channels and each channel
contained numerous ellipse-shaped micropillars. The major
diameter of these pillars was 50 mm and the minor diameter was
30 mm with the between-pillar spacing of 50 mm. Micropillar
platforms were modified by deposition of activated partial
thromboplastin time (aPTT) clot activating reagents.
A 1.35 mL aliquot of a stock solution of human fibrinogen
labelled with Alexa Fluor 488 (Molecular Probes, F-13191) was
added to 15 mL of citrated control plasma (HemosIL, Instru-
mentation Laboratory B.V., Netherlands). 15 mL of 0.025 M
CaCl2 solution (Stago Diagnostica) was then added to reverse the
effect of citrate and allow clotting. Immediately after addition of
Ca2+ ions, 25 mL of a test mixture was applied to an aPTT-coated
test chip and the measurement was started. Blank controls were
prepared by replacing CaCl2 with NH4Cl in order to avoidAnalystrecalcification, prevent clotting and maintain the dilution factor
and ionic strength.
Clot formation was observed using bright light and fluores-
cence microscopy. Measurements were performed using an
optical system (Fig. 1c) consisting of a CCD camera (Hama-
matsu Orca ER) attached to an Olympus IX81 fluorescent
microscope equipped with a climate chamber and heating block
and a motorised stage. Fluorescence signals were monitored
using the following settings: magnification: 10, excitation at
488 nm and emission at 519 nm, exposure time: 21 ms. The
autofocus and the brightness auto-adjustment functions were
switched off at all times. Experiments were performed in a dark
room at 37 C.
An area of the micropillar platforms of approx. 650  820 mm
was imaged every 10 s for up to 1500 s (Fig. 1d). Each image was
converted to an array of 1360  1024 pixels (N > 1.39  106),
each one outputting a value of fluorescence intensity (Fig. 1e).
Each frame was output as an .avi file to a LabView interface
which automated calculation of the mean fluorescence and
standard deviation (SD) for each frame. Change in the absolute
fluorescence signal was monitored. The change in the distribu-
tion of the label in the monitored area was also assessed using
measurements of SD of the averaged fluorescence signal. The
recorded data were also subject to visual analysis, where neces-
sary. The maximum fluorescence signal detection was set
according to the optical limitations of the microscope, while the
minimum level of fluorescence signal detected by the camera was
varied from 0 to 70 arbitrary fluorescence units (f.u.) in order to
determine an optimum setting for clotting time (CT) determi-
nation in normal clotting and heparinised control plasmas. The
effect of heparin concentration on the fluorescent profiles was
investigated by spiking the citrated platelet poor plasma with
unfractionated heparin (Sigma) at concentrations of 0–2 U mL1
according to manufacturer’s data.
Three detection areas were investigated along the lateral flow
platform surface at three locations along the 20 mm flow path in
order to select an area that would reflect the onset of clotting in
the most reliable way (Fig. 1a).
The effect of evaporation of a standard clotting sample
consisting of plasma and CaCl2 at a 1 : 1 ratio supplemented
with fluorescently labelled fibrinogen (total volume 25 mL) and
applied to the microfluidic platform modified with the aPTT-
SP reagent was investigated by measuring the percentage loss
of a sample mass over a period of 38 min using a standard
laboratory balance.
Following on from the establishment of the assay principle,
more detailed assay optimisation was undertaken. Variables
including aPTT reagent type and volume were optimised with the
aim of establishing clear and reproducible fluorescence clotting
profiles from which to extract CTs which could be modified by
heparin levels.Results and discussion
Investigation of the clot formation and localisation principle
The nature of the clot formation and localisation phenomenon
was initially explored on a microstructured surface composed of
cyclic polyolefin, fabricated by injection moulding. This deviceThis journal is ª The Royal Society of Chemistry 2011
Fig. 1 Experimental setup for development of the fluorescent lateral flow assay. (a) Polymeric platforms made from cyclic polyolefin with a lateral flow
zone composed of micropillars of 65–70 mm in height, top diameter ca. 50 mm, base diameter ca. 70 mm, distance between the centres of the pillars in
a row of 85 mm, and distance between the centres of the pillars in a column of 185 mm and (b) microfabricated glass substrate with 2 mm wide channels,
each channel containing ellipse-shaped micropillars of major diameter 50 mm and a minor diameter of 30 mm with the between-pillar spacing of 50 mm.
Platforms were modified with deposited clotting reagents and placed in a fluorescence microscope with CCD camera (c). Following addition of blood
sample to the platforms, the fluorescence response was monitored in an area of the platforms 650 820 mm (d). The imaged area was captured every 10 s
and converted to an array of light intensity values (e) and output to a video image file which was processed by a LabView interface.
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View Onlinehad been patterned into a lateral flow arrangement (Fig. 1a).
Initially, changes in fluorescence were monitored in the centre of
the test channel (area 2).
A conjugate of human fibrinogen labelled with Alexa Fluor
488 was used in the assay at a concentration of 5% of normal
fibrinogen content in plasma. There was no action required to
release a fluorescent signal. In the presence of thrombin the
soluble fibrinogen was converted into insoluble fluorescently
labelled fibrin. In essence, the labelled fibrin then competes for
unlabelled fibrin for incorporation into the forming clot allowing
its optical fluorescent localisation. Additionally, binding of the
labelled fibrin to the GPIIIb-IIa receptor on activated platelets
could take place which would supplement the process of fibrin
incorporation into a clot. To assess the potential of the fluores-
cent label to be used to detect clot formation in vitro, a plasma
test sample was externally recalcified and supplemented with the
fluorescently labelled fibrinogen. A sample was applied to
a microfluidic chip that had previously been modified by drying
aPTT-SP reagent onto the surface. Passage of the liquid sample
would lead to solubilisation and reconstitution of the reagent
which would then bring about accelerated clotting.
It was found that the sample advanced along the device
channel in a highly controlled and reproducible fashion with an
initially uniform distribution of the dye. When analysed by lightThis journal is ª The Royal Society of Chemistry 2011microscopy, immediately after addition of sample, the mixture
was homogeneous (Fig. 2a). However, after 10 min, strands
which were believed to be fibrin fibres could be seen gathering
around and between the micropillars (Fig. 2b). When analysed
using fluorescent microscopy, initially, there was an even distri-
bution of fluorophore with relatively low average background
intensity (Fig. 2c). However, following clotting, patches of more
intense fluorescence in a pattern similar to that seen for the fibrin
fibres under light microscopy could be seen (Fig. 2d). It could
also be seen that there was a decrease in fluorescence in areas
immediately adjacent to the areas of more intense clot formation,
which may be due to the concentration of the labelled fibrinogen
within the loci of forming clots.
The concentration of the fluorescently labelled fibrinogen and
its distribution along the channel appeared to be changing in
a time-dependent manner. Appearance of the highly fluorescing
formations could be observed after approx. 300 s (Fig. 2d), which
corresponded to the time needed for fibrin fibre formation as
observed visually by light microscopy (Fig. 2b). Therefore, the
timing of the localisation of clot formation as seen with fluo-
rescence could form the basis of a means of defining an assay CT.
Plasma samples were spiked with a range of heparin concen-
trations (0–1 U mL1) in order to obtain samples with prolonged
CTs (Fig. 3). The change in the average fluorescence over timeAnalyst
Fig. 2 Images of recalcified plasma sample supplemented with fluo-
rescently labelled fibrinogen and tested in aPTT reagent-coated (aPTT-
SP) lateral flow platforms captured using (a) bright light microscopy,
20, at 5 s, (b) bright light microscopy, 20, at 10 min, (c) fluorescence
microscopy, 10, at 5 s and (d) fluorescence microscopy, 10, at 10 min.
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View Onlinewas monitored at the centre of the lateral flow device. All samples
showed some initial increase in fluorescence intensity, due to the
influx of label to the area as it passed down the channel. At some
point, however, there was an actual decrease in fluorescence
intensity, followed once again by a gradual rise. The point at
which this decrease occurred appeared to correlate with the
concentration of heparin used, rising from approx. 130 s at 0 U
mL1 to approx. 220 s for 1 U mL1. However, the profiles
generated were not very well defined, particularly at 1 U mL1 in
which the change in the profile was difficult to interpret. Thus,
alternative methods of correlating clotting with changes in
fluorescence were investigated.Fig. 3 Change in mean fluorescence intensity with time measured for
fluorescent label-supplemented plasma samples spiked with 0 (circles),
0.25 (squares), 0.5 (triangles) and 1 (crosses) U mL1 of heparin tested in
aPTT-SP-coated microfluidic channels.
AnalystAlthough it did not appear reliable to extract the CT values
from the total change in fluorescence intensity, visual observa-
tion had suggested that, as well as changes in the average fluo-
rescence, the localised redistribution of the label within a specific
area might also be changing in a time-dependent manner.
Therefore, the fluorescence standard deviation (SD) of the
monitored zone was assessed.
Fig. 4 shows the change in SD of the fluorescence over time
obtained for 0.25 U mL1 of heparin in plasma with the fluores-
cence background detection set between 0 and 70 f.u. The shapes
of the profiles obtained for this sample were shown to be highly
dependent on the background fluorescence setting. Since all data
points in the monitored area were included in the SD measure-
ment, even low signal areas such as the micropillar surface were
included in the SD calculation. Increasing the background cut off
resulted in the elimination of the low signal regions within the
monitored area (most likely coming from the areas of micro-
pillars) and thus lower SD values were obtained. Thus, below 30
f.u., initial SD values were greater than zero, being between 3 and
4 for 0 f.u. and between 2 and 3 SD for 10 f.u. However, above 30
f.u., little or no change in SD was recorded during the initial
profile, which suggests that there was no discrimination between
background levels of fluorescent label and the chip substrate.
At approx. 400 s, however, there was a large increase in SD
irrespective of background settings, which was most likely due to
the onset of coagulation. At this point, samples with background
cut-offs of 20 f.u. or greater exhibited sharp, but erratic increases
in SD, whereas at 0 and 10 f.u., the profiles were smooth, but less
pronounced in terms of rate of change and peak SD achieved.
The changes in SD for the profiles corrected for background
above 30 f.u., combined with the absolute fluorescence values
obtained in Fig. 3 suggest that the distribution of fluorescent
label within the measured area must be changing, becoming
reduced in some areas and increased in others and that this
phenomenon appears to be associated with the onset of clotting.
In addition, the change in SD became more significant during
clotting for profiles at 20 f.u. cut off or more, while at the same
time the signal-to-noise ratio was reduced resulting in noisier
profiles which, in turn, made CTs more difficult to determine. On
the other hand, the change in SD obtained with no background
rejection (0 f.u.) was slow and gradual and the first point ofFig. 4 Change in SD over time obtained for plasma sample spiked with
0.25 U mL1 heparin. Data analysed using LabVIEW software at the
minimum signal detection settings of the camera between 0 and 70 f.u.
This journal is ª The Royal Society of Chemistry 2011
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f t
he
 W
es
t o
f E
ng
la
nd
 o
n 
21
 M
ar
ch
 2
01
1
Pu
bl
ish
ed
 o
n 
04
 F
eb
ru
ar
y 
20
11
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C0
AN
009
07E
View Onlinea change in SD was not well-defined. However, at 10 f.u. cut-off,
the initial SD was still quite low, while the change in SD observed
during coagulation was quite pronounced and not subject to
noise and variability.
The time between the start of the assay and the onset of the
large change in SD was suggested to equate with the sample CT
and these values were determined from the data shown in Fig. 4.
To corroborate this, visual examination of the recorded frames
was performed. The time points when the creation of the first
fibrin fibres could be visually observed were defined as the CT
and compared to the CT values which were taken as the time
points of sudden increase in SD (Table 1).
At the minimum signal detection settings of 0 and 10 f.u., CT
values could be reliably extracted from the SD profiles in Fig. 4,
while CT determination on the basis of profiles at detection
minima of 20 f.u. or greater was very difficult or impossible to
perform. The visual analysis was used as a correction method
indicating a ‘‘real’’ time point for clot initiation. The minimum
setting of 0 or 10 f.u. allowed CT determination in a relatively
reliable way. Prolongation in CT values was observed with
increased heparin concentration for both settings. However,
analysis at 10 f.u. correlated best with the values determined by
visual observation for all tested heparin concentrations and
reflected the onset of clotting in a more reliable way than for
0 f.u. By setting the detection minimum to 10 f.u., areas of very
low fluorescence signal were neglected, which included micro-
pillars as the darkest areas. Excluding these regions from the SD
analysis yielded more reliable results. Analysis at the minimum
signal detection of 10 f.u. allowed reliable and accurate CT
determination and therefore, was chosen as an appropriate
method for further CT determination.
Thus, it has been shown that the change in the distribution of the
fluorescence signal correlated very well with the formation of fibrin
fibres as observed visually, and that this could be used as a means
of identifying the onset of coagulation in a clotting sample.Evaluation of the assay on a glass substrate
In addition to the polymeric (cyclic polyolefin) substrate used for
the assay development discussed above, a microstructured glassTable 1 CT values for plasma samples containing 0–2 U mL1 of heparin ob
Fig. 4. (—) refers to a meaningless or indeterminate CT read-out
Heparin concentration/U mL1
CT/s
Visual analysis
Minimum of s
0 10
0 290 290 29
290 330 30
280 280 29
0.25 350 350 35
340 340 34
400 410 40
0.5 470 470 47
460 480 48
470 480 48
1 500 640 64
500 500 50
480 490 49
2 560 580 56
This journal is ª The Royal Society of Chemistry 2011substrate was also evaluated for the assay (Fig. 1b). Glass
functions as a reference material for the development of coagu-
lation time tests since glass is known to potentiate the intrinsic
coagulation process and has been used as the foundation of
blood clotting tests since the establishment of the Lee and White
test in 1913.22 Other work has shown that polymeric substrates
modified with glass-like surfaces can accelerate coagulation in
CT tests.23
The redistribution of the fluorescence label during the clotting
of a plasma sample supplemented with fluorescently labelled
fibrinogen was monitored using fluorescence microscopy on the
aPTT-coated glass chips for 710 s. Representative images
captured at 100, 280 and 500 s are shown in Fig. 5. The moni-
tored area was initially dark with evenly distributed fluorescence
signal (Fig. 5a). The presence of brightly fluorescing formations
could be observed in Fig. 5b. Following that an increase in signal
intensity was observed but the signal was mostly confined around
the micropillars (Fig. 5c). Despite the differences in the platform
design, micropillar shape, channel and micropillars dimensions
between this platform and the previously used 4Castchip,
a similar trend of the fluorescence signal redistribution as an
effect of clotting was observed. The results indicate that our
assay is universally applicable to different microfluidic substrate
materials.
In order to quantitatively determine the onset of clotting,
images were analysed by calculation of a change in mean fluo-
rescence intensity with time and using SD calculations (Fig. 6).
The clotting sample initially showed some short term increase
in mean fluorescence intensity. At some point, however, there
was an actual decrease in fluorescence intensity, followed once
again by a gradual rise. It was not possible to correlate the
changes in fluorescence intensity with the clotting process and
indicate the onset of clotting on the basis of this result. Thus, the
SD of the fluorescence intensity was investigated.
For the first 250 s only small changes in SD were observed. At
this stage the signal was uniformly distributed within the moni-
tored area (Fig. 5a). After this period, an increase in SD was
observed. This period was associated with the redistribution of
the fluorescent label (Fig. 5b) and which, as previously suggested,
corresponds to the onset of clotting. A continuous increase in thetained by visual analysis and on the basis of the SD response profiles in
ignal detection/f.u.
20 30 40 50 60 70
0 — — 260 — — —
0 — 350 — — 290 —
0 — — — — — —
0 360 370 350 — — —
0 350 — — — — —
0 — 390 420 — — —
0 — — — — — —
0 — — — — — —
0 480 480 — 480 — —
0 — — 640 640 — 470
0 510 — — — — —
0 470 — — — — —
0 480 — 480 500 — —
Analyst
Fig. 5 Images of the glass micropillar test channel modified with aPTT-
SP reagent, containing normal clotting plasma sample supplemented with
fluorescently labelled fibrinogen captured using fluorescence microscope
with attached video camera at (a) 100 s, (b) 280 s and (c) 500 s after
sample application. Magnification used: 10. The inset shows the
magnified (20) localised redistribution of a fluorescence label during
clotting.
Fig. 6 Change in the mean fluorescence intensity (open circles) and the
SD of the fluorescence intensity (filled circles) over time for a plasma
sample supplemented with fluorescently labelled fibrinogen on the glass
micropillar channel modified with aPTT-SP reagent. Arrow indicates the
time point for the appearance of highly fluorescent regions. Signal
measurement interval: 10 s.
Analyst
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View OnlineSD started at around 350 s. Similar to the previously tested
platform, increased localised signal was observed around the
pillar, which was most likely an indicator of the onset of evap-
oration (Fig. 5c). The label accumulation and signal enhance-
ment in the circles around the pillars and decreased intensity in
the areas between pillars caused significant changes in the SD,
which could be correlated with the appearance of a high peak in
SD vs. time profile at approx. 550 s in Fig. 6. Eventually, evap-
oration seemed to affect areas adjacent to the pillars as well,
which could be observed in a gradually decreasing SD signal. As
all the liquid evaporated, the fluorescence signal was quenched.
It has been shown that the approach based on the redistribu-
tion of the fluorescently labelled fibrinogen during clotting of an
activated plasma sample can be successfully utilised to monitor
clot formation, localisation and the determination of the clotting
initiation on both polymer and glass micropillar substrates.
Although the assay was shown to be possible on the glass
substrate, further development and optimisation were performed
on the polymer-based platform both for the quality of responses
and because of the availability of large numbers of chips for
assay development.Selection of test location
Typical clot monitoring tests were carried out according to the
method developed above. The testing took place in the polymer
lateral flow platforms coated with 40 mL of aPTT chemistry
(SynthASIL). The measurement started with application of a test
sample to the sample zone where it came in contact with the dried
aPTT chemistry. The whole area of the test channel containing
immobilised aPTT reagent became filled with the test sample and
was examined in order to select the most appropriate measure-
ment location to monitor clot progression in the most repro-
ducible and reliable manner. Clotting of plasma samples
containing 0, 0.25 and 0.5 U mL1 of heparin was monitored and
recorded in areas 1, 2 and 3 as indicated in Fig. 1a.
The collected data were analysed in terms of the SD change
over time for normal clotting and heparinised samples monitored
in each of the three areas in the channel (Fig. 7). It was shown
that the redistribution of fluorescent label was different at zones
along the test channel. The CT values for normal and heparinised
plasma samples were similar in areas 1 and 2, with the exception
of the 0.5 U mL1 heparin concentration which affected the
clotting process so dramatically that there was little (areas 2 and
3) or no (area 1) increase in SD over time, which made the CT
calculation impossible. The CTs of the profiles for area 3 were
significantly prolonged in comparison to those obtained for areas
1 and 2. There was only a minor increase in SD in area 3 for
a normal clotting sample (0 U mL1 heparin) at around 600 s,
which could suggest that the clotting occurred but there was only
a limited amount of free fluorescent label available and therefore
the signal was very low. A significant change in SD for hepari-
nised samples was observed after more than 1200 s. It was not
confirmed if this was due to the occurrence of clotting or some
other event. The reason for the low and delayed change in SD
recorded in area 3 was not clear. Possibly the portion of plasma
that reached the last stages of the journey along the channel
could be partly depleted of fibrinogen and/or other coagulation
factors which were consumed for clot formation in the earlyThis journal is ª The Royal Society of Chemistry 2011
Fig. 7 Change in SD over time for plasma containing 0 (circles), 0.25
(squares) and 0.5 U mL1 (triangles) heparin measured in three areas in
the test channel: area 1 representing beginning, area 2, middle and area 3,
end of the test channel.
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f t
he
 W
es
t o
f E
ng
la
nd
 o
n 
21
 M
ar
ch
 2
01
1
Pu
bl
ish
ed
 o
n 
04
 F
eb
ru
ar
y 
20
11
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C0
AN
009
07E
View Onlinestages of the channel (areas 1 and 2). Alternative explanations
could be adsorption of fibrinogen and/or other coagulation
factors to the surface, which could have influenced the efficiency
and the rate of clot formation in the latter parts of the channel.
An important fact was discovered during visual inspection of
the channel filled with clotting solution. The delayed SD increase
after 1200 s observed in area 3 might have been simply a result of
un-bound, free, labelled fibrinogen accumulating at the end of
the channel rather than clotting. The label accumulation couldThis journal is ª The Royal Society of Chemistry 2011have brought about an increase in the overall signal, and
therefore, overall SD. This could result in a false positive due
to the rapid increase in SD which does not correspond to labelled
fibrinogen incorporation into the clot, but simply label
accumulation.
The profiles obtained for area 2 were clear and distinct in
comparison to area 1 where the 0.25 U mL1 profile consisted of
three steps. Without exhaustive visual analysis it would be
impossible to find out which of those three steps corresponded
to the initiation of the clotting process. Therefore, area 2
was selected as the most appropriate location for further CT
determination.
The absolute CTs were relatively long, being approx. 600 s for
normal clotting plasma and longer again for heparinised
samples. This may be due to the nature of the aPTT reagent used
(SynthASIL) (i.e. activity in a dried form, the time required for
its release from the surface and physical characteristics of the
reagent components such as solubility, etc.). It should also rec-
ognised that the developed method is a one-step assay where the
contact activation takes place within the test channel and so the
time required for the contact activation is included in the total
CT value. Therefore, this value does not correspond to the
typical aPTT normal CT range given by the manufacturer, which
is typically obtained by the standard aPTT procedure that
involves a 3 min long pre-incubation step at 37 C.Effect of evaporation
The potential impact of evaporation on the test was assessed over
a prolonged period of time in the polymer lateral flow device,
which was not equipped with a lid and therefore was exposed to
atmospheric conditions. A standard clotting solution consisting
of 1 : 1 mixture of plasma and CaCl2 supplemented with fluo-
rescently labelled fibrinogen (total volume 25 mL) was applied to
the microfluidic platform modified with the aPTT-SP reagent.
The percentage loss of mass was measured using a standard
laboratory scale and was taken as the evaporation rate (ESI†).
It was shown that the evaporation process was linear under the
given conditions for approx. 1500 s (25 min) at which time it
reached a plateau and only approx. 6% of the initial sample mass
remained. At approx. 780–840 s (13–14 min) 50% of the sample
mass had evaporated. Previously observed changes of the fluo-
rescence SD signal due to label relocation were attributed to
evaporation, especially for times longer than 780–840 s. It was
also established that the first 600 s (10 min) (in the case of
a normal clotting sample) was the period that should be moni-
tored, as although 38% of sample mass had been lost, this did not
impact on the measurement of coagulation. However, after
approx. 780 s (13 min) the measurement was more significantly
influenced by evaporation with nearly 50% loss of sample mass
and should not be used for CT measurement.Effect of coagulation reagent type
The lateral flow platforms were modified with 40 mL of either
Cephalinex, C.K. Prest 2, SynthASIL, aPTT-SP or TriniCLOT
aPTT S. Tests were performed on normal plasma and plasma
samples spiked with 0.5 U mL1 heparin (0.25 U mL1 in the case
of SynthASIL as 0.5 U mL1 prolonged the plasma CT soAnalyst
Table 2 CT values calculated for normal clotting (0 U mL1 heparin)
and heparinised (0.5 U mL1 and 0.25 U mL1 for SynthASIL) plasma
samples tested on platforms modified with dried aPTT reagents
aPTT reagent
CT/s
Normal Heparinised
Cephalinex 360 420
C.K.Prest 2 260 580
aPTT-SP 240 430
TriniCLOT aPTT S 290 370
SynthASIL 600 950
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View Onlinedrastically that it was impossible to estimate a CT before the
sample evaporated). Fig. 8 illustrates the associated clotting
profiles obtained for chips modified with these aPTT reagents
and Table 2 summarises the extracted CTs obtained for the five
tested reagents.
It was difficult to extract the CT values for the samples acti-
vated with Cephalinex and C.K. Prest 2 on the basis of the
profiles shown in Fig. 8. The change in signal SD was gradual
throughout the clotting process and therefore the CTs were not
well-defined. However, small inflections in the responses could be
observed and so CTs of 360 s and 420 s for Cephalinex and 260 s
and 580 s for C.K. Prest 2 were given for normal and heparinised
samples, respectively. SynthASIL did show a clear inflection in
the SD response and yielded a CT of 600 s for normal clotting
plasma, which was nearly two-fold longer than CT achieved with
any other tested reagent. High baseline CT values would not be
suitable for further assay development, therefore the use of
SynthASIL was not considered as an optimal strategy for the
assay chemistry formulation. The profiles obtained for aPTT-SP
and TriniCLOT aPTT S showed very distinctive changes in SD
upon clot formation; the profiles were clear, devoid of noise and
thus the CT values were easy to determine for both normal
clotting as well as for heparinised samples. However, the delay in
clotting due to the addition of heparin was not as significant forFig. 8 Change in fluorescence SD over time obtained for 0 U mL1 (open circl
in plasma tested on platforms modified with aPTT reagents.
AnalystTriniCLOT aPTT S as it was for aPTT-SP. The difference in CT
between 0 and 0.5 U mL1 of heparin was only 80 s for Trini-
CLOT aPTT S in comparison to 190 s for aPTT-SP. In the case
of TriniCLOT aPTT S it would be difficult, if not impossible, to
distinguish between 0 and 0.25 and between 0.25 and 0.5 U mL1
of heparin in a sample. On the other hand, TriniCLOT aPTT S
could be employed in assays for high heparin dosage monitoring
(over 2 U mL1), i.e. during surgery. The CT obtained for non-
heparinised sample activated with aPTT-SP was the shortest of
all the tested reagents (240 s) and addition of 0.5 U mL1 of
heparin resulted in a significant CT prolongation (430 s). aPTT-
SP was thus chosen as the most reliable reagent providing thees) and 0.5 U mL1 (or 0.25 U mL1 for SynthASIL) (filled circles) heparin
This journal is ª The Royal Society of Chemistry 2011
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View Onlineshortest CT and good differentiation between low heparin dose
concentrations and was used for further development of the
device for monitoring of therapeutic level of anticoagulant (0–2
U mL1).Fig. 9 Calibration curve showing relationship between the concentra-
tion of heparin in spiked human plasma samples and the resulting clot-
ting time extracted from the SD profiles as derived from the fluorescence
response of the assay (n ¼ 3 except for 2 U mL1 where n ¼ 1).Effect of coagulation reagent volume
Typically, a ratio of 1 : 1 of plasma to aPTT reagent in aPTT
determination using the tilting tube method or in a plate-based
assay is recommended by aPTT formulation manufacturers. The
designed device consisted of a channel coated with a dried
formulation of aPTT chemistry. Therefore, the ratio of plasma
and aPTT could not be equivalent to the ratio in standard assays.
The total volume of the test mixture would not be in homoge-
neous contact with the aPTT chemistry immediately following
mixing. Typically, it took 40–60 s for a sample to fill the test
channel. Therefore, a study aimed at determining the optimum
aPTT reagent volume (and therefore mass) for deposition was
performed. 10–50 mL of aPTT-SP were drop-coated in the test
channel and dried. Regardless of the reagent volume the whole
area of the test channel was covered due to capillary filling of the
reagent in the channel. Normal clotting (no heparin) and hep-
arinised (0.5 U mL1) samples were tested in duplicate or tripli-
cate.
The SD profiles for 10–50 mL of aPTT showed similar trends
(ESI†). The change in the SD value was delayed for heparinised
plasma in comparison to that of normal clotting plasma for all
tested aPTT volumes. The average CTs were between 245–300 s
and 400–420 s for normal clotting (0 U mL1 heparin) and spiked
(0.5 U mL1 heparin) plasma samples, respectively. Surprisingly,
there was no significant difference in the CTs obtained for
plasmas triggered with aPTT deposited at different volumes.
Even a five-fold difference in the aPTT reagent volume did not
bring about any significant change in the CT value. It has been
shown that even low aPTT reagent to plasma ratios were capable
of effectively activating the sample. However, significant differ-
ences in the quality of the obtained SD vs. time profiles were
noticed, which was a significant factor in the CT determination.
The use of 10 and 20 mL aPTT was shown to generate noisier
profiles resulting in less obvious inflections and greater difficulty
in CT determination. In comparison, 30 or 40 mL profiles were
well-defined and CTs could be easily assessed. 50 mL was as good
as 30 and 40 mL. However, such a high volume was difficult to
apply. Therefore, 30 mL was selected as an optimum volume of
an aPTT reagent to be used in the further assay platform
development.Calibration in heparin-spiked human plasma samples
Following optimisation of the assay with regard to the choice of
microstructured platform (polymeric), type of aPTT assay
reagent (aPTT-SP), reagent volume (30 mL), measurement loca-
tion (area 2) and the optimal measurement settings for the
detection of changes in standard deviation upon clotting (back-
ground cut off at 10 f.u.), a calibration was performed using
human serum samples spiked with a range of heparin concen-
trations from 0 to 2 U mL1 (n ¼ 3 for all samples except 2 U
mL1 where n ¼ 1). The extracted clotting time responses are
shown in Fig. 9. The data show that there is good differentiationThis journal is ª The Royal Society of Chemistry 2011of heparin concentration up to 1.5 U mL1, but the assay begins
to plateau at 2 U mL1. This observation is broadly in line with
most measures of heparin using aPTT tests which rarely exceed 1
to 1.5 U mL1 heparin in spiked samples.24 The standard devi-
ations were acceptable in all cases except for 1 U mL1 heparin.
However, it should be noted that as a sample frame is only taken
every 10 s, considerable imprecision is introduced into the
determination of the clotting time as it can deviate by a minimum
of 10 s. Further optimisation of the system to capture data
more rapidly may improve this. Nevertheless, the potential for
the device to be used to measure aPTT clotting time has been
illustrated. This work forms the foundation for further optimi-
sation of the assay for clinical measurement of heparinised blood
samples.Conclusion
The ability to identify the onset of in vitro clot formation using
the redistribution of a fluorescently labelled fibrinogen marker
was demonstrated. It was shown that in both polymeric and glass
microstructured lateral flow device platforms, the fluorescent
label becomes redistributed due to its incorporation into the
forming clot, which leads to changes in the fluorescence SD over
time. These changes were shown to correlate with the formation
of fibrin fibres and thus the onset of coagulation. The system was
further optimised in terms of the impact of evaporation on the
assay, the choice of location for monitoring clot formation and
the type and amount of reagent required to bring about activa-
tion of the clot in the channel. The platform could be applied to
the development of specific assays for monitoring coagulation
and the impact of anti-coagulant drugs.Acknowledgements
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